Helen Varker, BS

Articles by Helen Varker, BS

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

ByBrenna L. Brady, PhD,Matthew Lucci, MPH,Kathleen Wilson, MPH,Kathleen M. Fox, PhD,Jeffrey Wojtynek, PharmD,Chelsea Cooper, PharmD,Helen Varker, BS,Christina Larson Chebili, MA,Igoni Dokubo, MD

We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

evidence-based oncology

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

ByBrenna L. Brady, PhD,Matthew Lucci, MPH,Kathleen Wilson, MPH,Kathleen M. Fox, PhD,Jeffrey Wojtynek, PharmD,Chelsea Cooper, PharmD,Helen Varker, BS,Christina Larson Chebili, MA,Igoni Dokubo, MD

Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

Evidence-Based Oncology

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

ByBrenna L. Brady, PhD,Matthew Lucci, MPH,Kathleen Wilson, MPH,Kathleen M. Fox, PhD,Jeffrey Wojtynek, PharmD,Chelsea Cooper, PharmD,Helen Varker, BS,Christina Larson Chebili, MA,Igoni Dokubo, MD

This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

Evidence-Based Oncology

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

ByBrenna L. Brady, PhD,Matthew Lucci, MPH,Kathleen Wilson, MPH,Kathleen M. Fox, PhD,Jeffrey Wojtynek, PharmD,Chelsea Cooper, PharmD,Helen Varker, BS,Christina Larson Chebili, MA,Igoni Dokubo, MD

Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.

Latest Updated Articles



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text